Your browser doesn't support javascript.
loading
Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.
Cheng, Yiming; Xue, Yongjun; Chen, Lu; Masin, Mark; Maciag, Paulo; Peluso, Teresa; Zhou, Simon; Li, Yan.
Affiliation
  • Cheng Y; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA.
  • Xue Y; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, NJ, USA.
  • Chen L; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA.
  • Masin M; Global Drug Development, Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
  • Maciag P; Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.
  • Peluso T; Global Drug Development, Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
  • Zhou S; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA.
  • Li Y; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA.
Br J Clin Pharmacol ; 89(1): 316-329, 2023 01.
Article in En | MEDLINE | ID: mdl-35981078
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Multiple Myeloma Type of study: Prognostic_studies Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Multiple Myeloma Type of study: Prognostic_studies Limits: Humans Language: En Year: 2023 Type: Article